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Objectives
To assess and compare acute treatment optimization as
measured by the Migraine Treatment Optimization
Questionnaire (M-TOQ) within a population-based
sample of persons with migraine.
Methods
AMPP is a longitudinal, US-population-based study for
which questionnaires were mailed to 24,000 severe head-
ache sufferers and followed annually. Respondents with
ICHD-2 migraine were stratified as either CM (>15 head-
ache-days/month) or EM (<15 headache-days/month).
Acute-treatment optimization was measured with M-
TOQ, a valid/reliable patient-report tool assessing
5 domains: functioning, rapid relief, relief consistency,
recurrence risk, tolerability over preceding 4 weeks.
Respondents rated statements in each area as either occur-
ring: never, rarely, < or > half the time. An item response
theory (IRT) model used to define scaled treatment opti-
mization scores as function of M-TOQ item set: lower
scores=less/problematic optimization; higher scores=grea-
ter optimization. The model was expanded to incorporate
persons with CM/EM on scaled scores and explored
demographic adjustments for age and gender.
Results
8612 persons met criteria for migraine (CM=539;
EM=8073) and completed M-TOQ. IRT model para-
meters indicated excellent M-TOQ psychometric proper-
ties. Scaled treatment optimization scores were
significantly lower for persons with CM (3.25) vs EM
(4.01, b=-0.757; p<.0001), corresponding to a 0.5 standard
deviation (SD) difference between CM and EM. After
adjustment, mean difference on scaled-optimization score
remained significantly lower (worse) for CM (b=-0.751;
p<.0001).
Discussion
Treatment regimens were less well-optimized and more
lacking in domains measured by M-TOQ (ie, functioning,
rapid relief, consistency of relief, risk of recurrence and
tolerability) among persons with CM vs EM. Funding: The
AMPP study was funded through a research grant to the
NHF from Ortho-McNeil Neurologics. Additional analyses
were supported by Allergan, Inc.
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